Overweight Clinical Trials in Chicago, Illinois

12 studies are recruiting for overweight in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Great Lakes Clinical Trials - West Wilson Avenue /ID# 282378, Chicago, Illinois

   Locations

   45 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

   This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the s…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University Of Chicago, Chicago, Illinois

   Locations

   80 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07571005 on ClinicalTrials.gov

3. AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

   This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will ei…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Chicago Research Center, Inc, Chicago, Illinois

   Locations

   92 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07571109 on ClinicalTrials.gov

4. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois

   Locations

   56 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

5. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

6. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Cedar Crosse Research Center, Chicago, Illinois

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

7. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Eagle Clinical Research, Chicago, Illinois

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

8. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Flourish Research - Great Lakes Clinical Trials, Chicago, Illinois

   Locations

   87 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

9. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois

   Locations

   117 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

10. A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

    The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the…

    Stage

    Phase 3

    Ages

    12 to 17

    Site

    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    34 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06672939 on ClinicalTrials.gov

11. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

    Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

    Stage

    Phase 3

    Ages

    18 to 79

    Site

    ACCOMPLISH-1 Research Site, Chicago, Illinois

    Locations

    71 in total

    Run by

    Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

    See if you can join NCT07654361 on ClinicalTrials.gov

12. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois

    Locations

    40 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov